Prasugrel: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
|||
| Line 18: | Line 18: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' | ''' [[Prasugrel indications and usage|Indications and Usage]]''' | ||
'''| [[Prasugrel dosage and administration|Dosage and Administration]]''' | '''| [[Prasugrel dosage and administration|Dosage and Administration]]''' | ||
'''| [[Prasugrel dosage forms and strengths|Dosage Forms and Strengths]]''' | '''| [[Prasugrel dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
| Line 34: | Line 34: | ||
'''| [[Prasugrel patient counseling information|Patient Counseling Information]]''' | '''| [[Prasugrel patient counseling information|Patient Counseling Information]]''' | ||
'''| [[Prasugrel labels and packages|Labels and Packages]]''' | '''| [[Prasugrel labels and packages|Labels and Packages]]''' | ||
<font color="#F8F8FF"> | |||
{| style="border: 3px solid #696969;" align="center" | |||
| style="background: #000000; border: 0px; padding: 0 5px; width: 800px;" | | |||
<center> | |||
'''WARNING: BLEEDING RISK''' | |||
</center> | |||
<center> | |||
''See full prescribing information for complete boxed warning.'' | |||
</center> | |||
<b> | |||
* Effient can cause significant, sometimes fatal, bleeding. | |||
* Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke. | |||
* In patients ≥75 years of age, Effient is generally not recommended, except in high-risk patients (diabetes or prior MI), where its use may be considered. | |||
* Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery. | |||
* Additional risk factors for bleeding include: body weight <60 kg; propensity to bleed; concomitant use of medications that increase the risk of bleeding. | |||
* Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient. | |||
* If possible, manage bleeding without discontinuing Effient. Stopping Effient increases the risk of subsequent cardiovascular events. | |||
</b> | |||
|} | |||
</font> | |||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 19:22, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Prasugrel, click here
Synonyms / Brand Names: EFFIENT®
Overview
Prasugrel is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently under clinical development in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel is a member of the thienopyridine class of ADP receptor inhibitors, like ticlopidine and clopidogrel (trade name Plavix). These agents are believed to reduce the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors.
Category
Cardiovascular Drugs:Antiplatelet drugs
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
|
WARNING: BLEEDING RISK See full prescribing information for complete boxed warning.
|
Mechanism of Action
Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.